Pharmafile Logo

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Springer Nature

Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote your approved branded drugs and medical devices to our audience…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that we attend each year.

View Profile

Company Details

New Jersey Headquarters, 24 N. Main St, Pennington, NJ, 08534, USA
855.662.6732

 Latest Content from PMHub 

B-lown away by our first CDP rating

Press Releases | April 13, 2023 | Cuttsy + Cuttsy

A catch up with Louise Jones, Cuttsy+Cuttsy's sustainability officer, on what was achieved in 2022, the agency's latest environmental assessment with CDP and a look ahead to 2023.

Expanding Access to High-Quality Healthcare

Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its...

Innovative Trials nominates Eloise Moffett as New VP of Commercial

Eloise Moffett joins Innovative Trials as New Vice President of Commercial to drive business growth globally

The ever-shifting landscape of health wearables

Back in 2018, we published a whitepaper discussing the growing trend of wearables in healthcare, along with the impact that this could potentially have on both patients and the healthcare...

Origins’ Knowledge Centre

A collection of resources including webinar recordings, publications and short videos to help you be more patient focussed

Powering Rapid Cognitive Analysis with AI

Dr. Tom Sawyer, CFO at Cognetivity Neurosciences, discusses the benefits of AI-driven dementia detection technology for patients, health care providers, and clinical research.To find out more about Impetus: https://www.meetwithimpetus.comImpetus Digital...

The speed of science and the pace of comms

Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes.

Virtual Patient Engagement Program: A Customer Story

Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease...

Putting Skin in the Game at AAD 2023

AAD has wrapped up in New Orleans, and the Medscape team have returned home from another successful conference.During the conference, Medscape hosted one educational symposium, Reframing the Management Approach for...

Humancomms for humancare?

Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023